Skip to main content
SpringerLink
Log in

Do Limitations in the Design of PARADIGM-HF Justify the Slow Real World Uptake of Sacubitril/Valsartan (Entresto)?

  • LETTER TO THE EDITOR
  • Published:
Cardiovascular Drugs and Therapy Aims and scope Submit manuscript

A Correction to this article was published on 01 October 2018

This article has been updated

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Change history

  • 01 October 2018

    The original version of this article unfortunately contained a mistake. There was a typo in the second sentence of the paragraph under the section Was the Dose of Drugs Fair?; "320 mg twice a day" should read "160mg twice a day". The corrected paragraph is shown below.

References

  1. Packer M, McMurray JJ, Desai AS, et al. PARADIGM-HF Investigators and Committees. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 2014; 371:993–1004.

    Article  Google Scholar 

  2. Uptake of new heart failure drug slow, say makers. http://www.cardiomyopathy.org/news%2D%2Dmedia/latest-news/post/126-uptake-of-new-heart-failure-drug-slow-say-makers. Updated November 6, 2015. Accessed 18 Oct, 2017.

  3. Packer M. Kicking the tyres of a heart failure trial: physician response to the approval of sacubitril/valsartan in the USA. Eur J Heart Fail. 2016;18:1211–9.

    Article  Google Scholar 

  4. Packer M, Armstrong WM, Rothstein JM, Emmett M. Sacubitril-valsartan in heart failure: why are more physicians not prescribing it? Ann Intern Med. 2016;165:735–6.

    Article  Google Scholar 

  5. Packer M, Poole-Wilson PA, Armstrong PW, Cleland JGF, Horowitz JD, Massie BM, et al. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. Circulation. 1999;100:2312–8.

    Article  CAS  Google Scholar 

  6. Khan MS, Fonarow GC, Ahmed A, Greene SJ, Vaduganathan M, Khan H, et al. Dose of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers and outcomes in heart failure: a meta-analysis. Circulation: Heart Failure. 2017;10:e003956.

    CAS  Google Scholar 

  7. Pablos-Mendez A, Barr RG, Shea S. Run-in periods in randomized trials: implications for the application of results in clinical practice. JAMA. 1998;279(3):222–5.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. School of Medicine, Oregon Health & Science University, Portland, OR, USA

    Rosa Ahn

  2. Division of Hematology Oncology, Knight Cancer Institute, Oregon Health & Science University, 3181 SW Sam Jackson Park Road, Portland, OR, 97239, USA

    Vinay Prasad

  3. Department of Public Health and Preventive Medicine, Oregon Health & Science University, Portland, OR, USA

    Vinay Prasad

  4. Center for Health Care Ethics, Oregon Health & Science University, Portland, OR, USA

    Vinay Prasad

Authors
  1. Rosa Ahn
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Vinay Prasad
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Vinay Prasad.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ahn, R., Prasad, V. Do Limitations in the Design of PARADIGM-HF Justify the Slow Real World Uptake of Sacubitril/Valsartan (Entresto)?. Cardiovasc Drugs Ther 32, 633–635 (2018). https://doi.org/10.1007/s10557-018-6830-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10557-018-6830-x

Search

Navigation